Protalix BioTherapeutics (PLX) Change in Receivables (2010 - 2026)

Protalix BioTherapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 381.67% year-over-year to -$6.4 million in Q1 2026; TTM through Mar 2026 was -$2.8 million, a 263.91% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, up 354.21% from the prior year.
• Change in Receivables fell to -$6.4 million in Q1 2026 per PLX's latest filing, from -$5.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $7.1 million in Q2 2024 and bottomed at -$8.4 million in Q3 2024.
• The 5-year median for Change in Receivables is $752000.0 (2024), against an average of -$71352.9.
• Across the five-year window, Change in Receivables soared 254.98% in 2023 and sank 881.65% in 2025, its largest moves.
• Year by year, Change in Receivables stood at -$4.5 million in 2022, then grew by 16.41% to -$3.8 million in 2023, then surged by 120.0% to $752000.0 in 2024, then sank by 881.65% to -$5.9 million in 2025, then retreated by 9.02% to -$6.4 million in 2026.
• Per Business Quant, the three latest PLX Change in Receivables figures stand at -$6.4 million (Q1 2026), -$5.9 million (Q4 2025), and $4.8 million (Q3 2025).